Course Overview

Therapeutics for cancer are entering a new era, where precision approaches promise to revolutionize the way in this disease is treated. This comprehensive course reviews current and emerging drugs, immunotherapies, their application to specific cancer types, how to conduct clinical trials for oncologic therapies, and the drug development process for drug candidates leading to their approval. The US Food & and Drug Administration (FDA) regulatory considerations for Oncology drugs, registration endpoints, and accelerated and Breakthrough approval mechanisms are also covered.

Benefits of Attendance

  • Understand cancer and different treatments including emerging immunotherapies
  • Learn clinical endpoints needed for review and regulatory approval
  • Learn about operations and presentations, important for Advisory Committees
  • Be able to discuss various cancer types such as lung, breast, colon, and others
  • Find out about clinical protocol designs and imaging techniques
  • Network with colleagues and experts in the oncology arena

Download the final course agenda for PERI’s comprehensive Cancer program.

  • Discuss the scope, nature and epidemiology of many human cancers with an emphasis on principles of case management of common malignancies
  • Describe specific applications of commonly used cancer treatments
  • Evaluate the design and conduct of oncology Phase I, II, and III clinical trials
  • Apply FDA requirements for oncology clinical trials and drug development programs to facilitate/expedite drug development
  • Overview of Oncology Drug Development
  • Cancer Types: Prostate, Lung, Breast, Colorectal, pancreas, other GI, Gynecologic, Kidney, Leukemias, Lymphomas, others
  • Emerging drugs, vaccines, other immunotherapies
  • Clinical Trial Designs; managing global trials and foreign data
  • Overview of US and EU Regulatory Guidances and Advisory Committees
  • Oncology-specific imaging techniques for protocols and registration
  • Clinical Team members
  • Project Clinicians
  • Clinical research associates or CRO staff
  • Regulatory affairs professionals
  • Product managers
  • Statisticians, data managers, medical writers
  • Marketing research staff
  • Anyone working in oncologic drug development or professionals moving to this area

Continuing Education Credit
Pharmaceutical Education & Research Institute, Inc. (PERI) is pleased to make continuing education credit available to you for attendance at this program. To receive credit, you must attend the entire program and submit the Continuing Education Application form directly to a PERI on-site coordinator. Additional $35 fee applies for students who are applying for continuing education credit.

ACPE Statement:
Pharmaceutical Education & Research Institute, Inc. (PERI) is accredited by the Accreditation Council for Pharmacy Education as a provider f continuing pharmacy education. ACPE Universal Activity Number is 0708-0000-17-005-L01-P. 1.95 continuing education units (CEUs) are available for this program. Initial Release Date: 10/25/17. This is a knowledge based CPE Activity.

ACCME Statement:
PERI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PERI, Inc. designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Event Details

Date: October 25-27, 2017
Location: One Washington Circle Hotel, Washington, DC 20037
Course Price: $1995
Early Bird Pricing: $1795

This course has concluded. Visit our course calendar to view upcoming scheduled programs.

Request a Proposal

Interested in bringing this course to your company? Request a proposal and a PERI team member will be in touch about hosting this course as a Corporate Education program.

Request Proposal

Request Proposal

Your Name (required)

Your Title (required)

Your Company (required)

Your Email (required)

Your Phone(required)

Subject of Interest(required)

Additional Information
(# Attendees, Location, Live/Online Learning, etc.)

How did you hear about us?

Course Information

Lauren Kirk
Course Manager
Email Question

Our Students

  • 1 “I have a better understanding of disease states and treatment options to draw from when planning clinical trials.”

  • 2 “I have a better appreciation of the bleakness of certain cancers for patient outcomes and the urgent need for development of effective treatments.”

  • 3 “I will now try to focus clinical terms on designing studies that are more focused on specific patient populations.”